Natera (NASDAQ:NTRA) Insider Sells $5,447,141.70 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 23,205 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the sale, the insider owned 144,992 shares in the company, valued at $34,035,422.08. This trade represents a 13.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total transaction of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total transaction of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The shares were sold at an average price of $191.46, for a total value of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $193,858.56.

Natera Stock Performance

Natera stock traded up $0.13 during midday trading on Thursday, reaching $242.91. The stock had a trading volume of 971,052 shares, compared to its average volume of 950,311. The stock has a market capitalization of $33.60 billion, a P/E ratio of -106.07 and a beta of 1.62. The firm’s fifty day simple moving average is $233.44 and its 200-day simple moving average is $190.60. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period last year, the company earned ($0.26) EPS. The company’s revenue was up 34.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NTRA. Piper Sandler boosted their price target on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. UBS Group lifted their target price on Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Morgan Stanley increased their price target on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a research note on Monday, January 12th. Finally, Barclays boosted their price target on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.50.

Institutional Investors Weigh In On Natera

Hedge funds have recently added to or reduced their stakes in the business. Horizon Investments LLC acquired a new position in shares of Natera in the third quarter valued at $32,000. Hilltop National Bank bought a new stake in shares of Natera during the 2nd quarter worth about $33,000. Sound Income Strategies LLC boosted its holdings in shares of Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after buying an additional 110 shares during the period. Flagship Harbor Advisors LLC acquired a new position in Natera in the 4th quarter valued at about $41,000. Finally, Quent Capital LLC bought a new position in Natera in the 3rd quarter valued at about $46,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.